Activation of Stat3 in Primary Tumors from High-Risk Breast Cancer Patients Is Associated with Elevated Levels of Activated Src and Survivin Expression
Autor: | Sandy Livingston, Craig A. Beam, Marek Wloch, Nills Diaz, Richard Jove, Tammy Bowman, Ibrahim Eweis, Susan Minton, Carlos A. Muro-Cacho, Ed Seijo, Roy Garcia, Charles E. Cox, Alan B. Cantor, Daniel M. Sullivan, Ji-Hyun Lee, Tanya Gritsko |
---|---|
Rok vydání: | 2006 |
Předmět: |
STAT3 Transcription Factor
Cancer Research Receptor ErbB-2 Survivin medicine.medical_treatment bcl-X Protein Estrogen receptor Antineoplastic Agents Apoptosis Breast Neoplasms Electrophoretic Mobility Shift Assay Docetaxel medicine.disease_cause Inhibitor of Apoptosis Proteins Clinical Trials Phase II as Topic Breast cancer Risk Factors Biomarkers Tumor Image Processing Computer-Assisted In Situ Nick-End Labeling medicine Humans Epidermal growth factor receptor Neoadjuvant therapy biology medicine.disease Immunohistochemistry Neoadjuvant Therapy Neoplasm Proteins Enzyme Activation ErbB Receptors Ki-67 Antigen src-Family Kinases Proto-Oncogene Proteins c-bcl-2 Receptors Estrogen Oncology Doxorubicin Cancer research biology.protein Female Taxoids Carcinogenesis Microtubule-Associated Proteins medicine.drug |
Zdroj: | Clinical Cancer Research. 12:20-28 |
ISSN: | 1557-3265 1078-0432 |
Popis: | Purpose: Constitutive activation of signal transducer and activator of transcription 3 (Stat3) protein has been observed in a wide variety of tumors, including breast cancer, and contributes to oncogenesis at least in part by prevention of apoptosis. In a study of 45 patients with high-risk breast cancer enrolled in a phase II neoadjuvant chemotherapy trial with docetaxel and doxorubicin, we evaluated the levels of Stat3 activation and potentially associated molecular biomarkers in invasive breast carcinoma compared with matched nonneoplastic tissues. Experimental Design: Using immunohistochemistry and image analysis, we quantified the levels of phospho-Stat3 (pY-Stat3), phospho-Src (pY-Src), epidermal growth factor receptor, HER2/neu, Ki-67, estrogen receptor, Bcl-2, Bcl-xL, Survivin, and apoptosis in formalin-fixed, paraffin-embedded sections from invasive carcinomas and their paired nonneoplastic parenchyma. The levels of molecular biomarkers in nonneoplastic and tumor tissues were analyzed as continuous variables for statistically significant correlations. Results: Levels of activated pY-Stat3 and pY-Src measured by immunohistochemistry were significantly higher in invasive carcinoma than in nonneoplastic tissue (P < 0.001). In tumors, elevated levels of pY-Stat3 correlated with those of pY-Src and Survivin. Levels of pY-Stat3 were higher in partial pathologic responders than in complete pathologic responders. In partial pathologic responders, pY-Stat3 levels correlated with Survivin expression. Conclusions: Our findings suggest important roles for elevated activities of Stat3 and Src, as well as Survivin expression, in malignant progression of breast cancer. Furthermore, elevated Stat3 activity correlates inversely with complete pathologic response. These findings suggest that specific Stat3 or Src inhibitors could offer clinical benefits to patients with breast cancer. |
Databáze: | OpenAIRE |
Externí odkaz: |